<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129739">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01413061</url>
  </required_header>
  <id_info>
    <org_study_id>AlloSource Subtalar Fusion RCT</org_study_id>
    <nct_id>NCT01413061</nct_id>
  </id_info>
  <brief_title>Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft</brief_title>
  <official_title>Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AlloSource</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AlloSource</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to evaluate the outcome of implanting AlloStem® graft
      with appropriate rigid internal fixation hardware as an alternative to autograft bone graft
      with rigid fixation in subtalar arthrodesis procedures. The primary objective of this
      clinical trial is to compare the overall fusion rate of the investigational to the control
      treatment. Fusion will be determined by clinical findings, radiographs and computed
      tomography (CT) of the subtalar joint 24 weeks (6 months) after the trial surgery.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fusion Rate (%)(as determined by CT assessment)</measure>
    <time_frame>6 months post-op</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic outcome assessments</measure>
    <time_frame>Pre-operatively, 6 weeks, 3, 6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome measurements</measure>
    <time_frame>Pre-operatively, 6 weeks, 3, 6, 12 and 24 months</time_frame>
    <description>FFI-R, SF-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome measurements</measure>
    <time_frame>Pre-operatively, 3, 6, 12 and 24 months</time_frame>
    <description>AOFAS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Degenerative Osteoarthritis</condition>
  <condition>Post-traumatic; Arthrosis</condition>
  <condition>Rheumatoid Arthritis and Other Inflammatory Polyarthropathies</condition>
  <condition>Rheumatoid Arthritis of Subtalar Joint</condition>
  <arm_group>
    <arm_group_label>AlloStem Live Cellular Allograft</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AlloStem is the combination of the Mesenchymal Stem Cells (MSC) derived from adipose with demineralized bone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control: Autologous Bone Marrow Aspirate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Autologous bone graft is recovered from the patient's own tibia or iliac crest, for transplantation in the subtalar joint.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Subtalar Arthrodesis</intervention_name>
    <arm_group_label>AlloStem Live Cellular Allograft</arm_group_label>
    <arm_group_label>Control: Autologous Bone Marrow Aspirate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must be diagnosed with degenerative osteoarthritis, post-traumatic arthritis,
             inflammatory arthritis (ie: rheumatoid arthritis) or other conditions of the hindfoot
             requiring subtalar arthrodesis.

          2. Patients must be able to attend follow-up examinations for the duration of the trial.

          3. The patient is at least 18 years of age and skeletally mature, or less than 80 years
             of age at the time of surgery.

          4. Is willing and able to comply with the clinical trial plan and able to understand and
             sign the Patient Informed Consent Form.

        Exclusion Criteria:

          1. Younger than 18 years old or older than 80 years old.

          2. Has a condition that prevents ambulation or completion of any of the trial
             measurements.

          3. Requires fusion of additional hindfoot or ankle joints simultaneously (i.e. a
             pantalar, tibiotalocalcaneal or triple arthrodesis). Concomitant midfoot or forefoot
             procedures, such as osteotomies, tendon or metatarsal procedures are not
             exclusionary.

          4. Has treatment planned for the arthrodesis which does not require the use of screws.

          5. Has any active infection of the hindfoot, a systemic infection or bacteremia.

          6. Has received any treatment within the past 12 months which may interfere with bone
             metabolism [bisphosphonates (Fosamax, Actonel, Boniva, Reclast) and calcitonin
             (Miacalcin)].

          7. Is scheduled to have any surgical procedure on the contralateral foot within 6 weeks
             before or after the study procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christiaan Coetzee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minnesota Orthopedic Sports Medicine Institute (MOSMI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Myerson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Foot and Ankle Reconstruction at Mercy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Anderson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orthopaedic Associates of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Juliano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Murphy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Campbell Clinic Orthopaedics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute for Foot and Ankle Reconstruction at Mercy</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopaedic Associates of Michigan</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Orthopedic Sports Medicine Institute (MOSMI)</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Campbell Clinic</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 29, 2015</lastchanged_date>
  <firstreceived_date>August 8, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Other Hindfoot Conditions requiring Subtalar Arthrodesis</keyword>
  <keyword>Post-traumatic Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
